目次

TABLE OF CONTENTS

1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
1.3.1 MARKET SEGMENTATION
1.3.2 INCLUSIONS AND EXCLUSIONS
1.3.3 REGIONS COVERED
1.3.4 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 STAKEHOLDERS
1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.2 RESEARCH APPROACH
2.2.1 SECONDARY DATA
2.2.2 PRIMARY DATA
2.3 MARKET SIZE ESTIMATION
2.3.1 KEY INSIGHTS FROM INDUSTRY EXPERTS
2.3.2 TOP-DOWN APPROACH
2.4 GROWTH RATE PROJECTIONS
2.5 MARKET BREAKDOWN AND DATA TRIANGULATION
2.6 RESEARCH ASSUMPTIONS
2.7 RESEARCH LIMITATIONS
2.8 RISK ANALYSIS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS
4.1 MICROCARRIERS MARKET OVERVIEW
4.2 NORTH AMERICA: MICROCARRIERS MARKET, BY PRODUCT & COUNTRY, 2023
4.3 MICROCARRIERS MARKET, BY END USER, 2024 VS. 2029
4.4 MICROCARRIERS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Increasing demand for cell-based vaccines
5.2.1.2 Rising technological advancements in microcarrier-based cell production tools
5.2.1.3 Growing investments in cell & gene therapy research
5.2.1.4 Rising preference for single-use technologies
5.2.1.5 Increasing R&D spending for biopharmaceutical production
5.2.2 RESTRAINTS
5.2.2.1 High cost of cell biology research
5.2.2.2 Limitations in high-density cell culture production
5.2.3 OPPORTUNITIES
5.2.3.1 Growing demand for 3D cell culture
5.2.3.2 Increasing demand for monoclonal antibodies and biosimilars
5.2.3.3 Growth potential in emerging economies
5.2.4 CHALLENGES
5.2.4.1 High costs associated with serum-free media
5.2.4.2 Complex microcarrier cell detachment process
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
5.4 PRICING ANALYSIS
5.4.1 AVERAGE SELLING PRICE TREND, BY PRODUCT
5.4.2 AVERAGE SELLING PRICE TREND OF KEY PLAYER, BY PRODUCT
5.4.3 AVERAGE SELLING PRICE TREND, BY REGION
5.5 VALUE CHAIN ANALYSIS
5.6 SUPPLY CHAIN ANALYSIS
5.7 ECOSYSTEM ANALYSIS
5.8 INVESTMENT/FUNDING ACTIVITY
5.9 TECHNOLOGICAL ANALYSIS
5.9.1 KEY TECHNOLOGIES
5.9.1.1 Flow cytometry
5.9.1.2 High-throughput screening technology
5.9.1.3 Single-use technology
5.9.2 COMPLEMENTARY TECHNOLOGIES
5.9.2.1 Nanotechnology
5.9.2.2 Artificial intelligence and machine learning
5.9.3 ADJACENT TECHNOLOGIES
5.9.3.1 Cell harvesting and separation
5.10 PATENT ANALYSIS
5.11 TRADE ANALYSIS
5.11.1 IMPORT DATA FOR HS CODE 841989
5.11.2 EXPORT DATA FOR HS CODE 841989
5.12 KEY CONFERENCES AND EVENTS, 2025-2026
5.13 REGULATORY LANDSCAPE
5.13.1 REGULATORY ANALYSIS
5.13.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.14 PORTER'S FIVE FORCES ANALYSIS
5.14.1 BARGAINING POWER OF SUPPLIERS
5.14.2 BARGAINING POWER OF BUYERS
5.14.3 THREAT OF NEW ENTRANTS
5.14.4 THREAT OF SUBSTITUTES
5.14.5 INTENSITY OF COMPETITIVE RIVALRY
5.15 KEY STAKEHOLDERS AND BUYING CRITERIA
5.15.1 KEY STAKEHOLDERS IN BUYING PROCESS
5.15.2 BUYING CRITERIA
5.16 IMPACT OF AI ON MICROCARRIERS MARKET
5.16.1 INTRODUCTION
5.16.2 MARKET POTENTIAL OF MICROCARRIERS
5.16.3 AI USE CASE STUDY
5.16.4 KEY COMPANIES IMPLEMENTING AI
5.16.5 FUTURE OF AI IN MICROCARRIERS MARKET

6 MICROCARRIERS MARKET, BY PRODUCT
6.1 INTRODUCTION
6.2 CONSUMABLES
6.2.1 MEDIA
6.2.1.1 Serum-based media
6.2.1.1.1 Increasing biopharmaceutical production to drive segment
6.2.1.2 Serum-free media
6.2.1.2.1 Need for improved control and reproducibility to augment growth
6.2.1.3 Other media
6.2.2 REAGENTS
6.2.2.1 Increasing focus on developing cell-based therapies to expedite growth
6.2.3 MICROCARRIER BEADS
6.2.3.1 Natural materials
6.2.3.1.1 Cellulose
6.2.3.1.1.1 Growing focus on sustainability in biopharmaceutical industry to boost market
6.2.3.1.2 Collagen
6.2.3.1.2.1 Shifting focus on personalized medicine to drive market
6.2.3.1.3 Alginate
6.2.3.1.3.1 Increasing demand for stem cell culture and regenerative medicine to aid growth
6.2.3.1.4 Other natural materials
6.2.3.2 Synthetic materials
6.2.3.2.1 Polystyrene
6.2.3.2.1.1 Increasing use of polystyrene for vaccine and monoclonal antibody production to support growth
6.2.3.2.2 Dextran
6.2.3.2.2.1 Growing utilization of dextran in cardiac regeneration, bone repair, and neurodegenerative diseases to fuel market
6.2.3.2.3 PLGA
6.2.3.2.3.1 Rising focus on 3D tissue engineering to encourage growth
6.2.3.2.4 Polyvinyl alcohol
6.2.3.2.4.1 Need for enhanced cell adhesion to advance growth
6.2.3.2.5 Other synthetic materials
6.2.3.3 Other materials
6.2.4 CELL CULTURE VESSELS
6.2.4.1 Increasing launches of 3D cell culture systems to augment growth
6.2.5 ACCESSORIES
6.2.5.1 Growing use of cell culture in industrial settings and bioreactors to drive market
6.2.6 OTHER CONSUMABLES
6.3 EQUIPMENT
6.3.1 BIOREACTORS
6.3.1.1 Stainless steel bioreactors
6.3.1.1.1 Rising focus on large-scale ease of production to boost market
6.3.1.2 Single-use bioreactors
6.3.1.2.1 Increasing use of single-use bioreactors by contract manufacturing organizations to stimulate growth
6.3.2 FILTRATION & SEPARATION EQUIPMENT
6.3.2.1 Growing adoption of advanced filtration & separation systems for bioprocess applications to drive market
6.3.3 CELL COUNTERS
6.3.3.1 Increasing research on cancer and stem cell to sustain growth
6.3.4 OTHER EQUIPMENT

7 MICROCARRIERS MARKET, BY APPLICATION
7.1 INTRODUCTION
7.2 BIOPHARMACEUTICAL PRODUCTION
7.2.1 VACCINE PRODUCTION
7.2.1.1 Shifting patterns in vaccine development and delivery to promote growth
7.2.2 THERAPEUTIC PROTEIN PRODUCTION
7.2.2.1 Growing applications of recombinant proteins to fuel market
7.3 TISSUE ENGINEERING & REGENERATIVE MEDICINES, BY THERAPY TYPE
7.3.1 CELL & GENE THERAPY
7.3.1.1 Increasing development of novel microcarriers to amplify growth
7.3.2 OTHER THERAPIES
7.4 TISSUE ENGINEERING & REGENERATIVE MEDICINES, BY CELL TYPE
7.4.1 STEM CELLS
7.4.1.1 Need for 3D environment for cell growth and differentiation to intensity growth
7.4.2 IMMUNE CELLS
7.4.2.1 Growing development of microcarrier beads to propel market
7.4.3 OTHER CELL TYPES
7.5 OTHER APPLICATIONS

8 MICROCARRIERS MARKET, BY END USER
8.1 INTRODUCTION
8.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
8.2.1 GROWING ADOPTION OF MICROCARRIERS FOR PRODUCTION OF VACCINES AND MONOCLONAL ANTIBODIES TO DRIVE MARKET
8.3 CONTRACT RESEARCH ORGANIZATIONS & CONTRACT MANUFACTURING ORGANIZATIONS
8.3.1 RISING FOCUS ON DRUG DISCOVERY, CLINICAL TRIALS, AND COMMERCIAL MANUFACTURING TO AID GROWTH
8.4 ACADEMIC & RESEARCH INSTITUTES
8.4.1 INCREASING COLLABORATIONS BETWEEN ACADEMIC INSTITUTES AND PHARMA COMPANIES TO AUGMENT GROWTH
8.5 CELL BANKS
8.5.1 GROWING FOCUS ON DEVELOPING ADVANCED TREATMENT METHODS TO PROPEL MARKET

9 MICROCARRIERS MARKET, BY REGION
9.1 INTRODUCTION
9.2 NORTH AMERICA
9.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
9.2.2 US
9.2.2.1 Robust investments for life science research to contribute to growth
9.2.3 CANADA
9.2.3.1 Growing advancements in regenerative medicine to drive market
9.3 EUROPE
9.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
9.3.2 GERMANY
9.3.2.1 Growing adoption of inorganic growth strategies by key players to boost market
9.3.3 FRANCE
9.3.3.1 Favorable government initiatives to intensify growth
9.3.4 UK
9.3.4.1 Rising focus on cancer research to expedite growth
9.3.5 ITALY
9.3.5.1 Increasing research on biotechnology, pharmaceuticals, and medical devices to promote growth
9.3.6 SPAIN
9.3.6.1 Rise in facility expansions and investments toward bioprocessing technologies to augment growth
9.3.7 SWITZERLAND
9.3.7.1 Favorable regulatory environment to boost growth
9.3.8 REST OF EUROPE
9.4 ASIA PACIFIC
9.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
9.4.2 CHINA
9.4.2.1 Growing inclination toward domestic production to drive market
9.4.3 JAPAN
9.4.3.1 Increasing geriatric population to foster growth
9.4.4 INDIA
9.4.4.1 Booming biotechnology industry to spur growth
9.4.5 SOUTH KOREA
9.4.5.1 Growing foreign investments to drive market
9.4.6 AUSTRALIA
9.4.6.1 Increasing focus on biomanufacturing to assist growth
9.4.7 REST OF ASIA PACIFIC
9.5 LATIN AMERICA
9.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
9.5.2 BRAZIL
9.5.2.1 Expanding pharmaceutical and biopharmaceutical industries to favor growth
9.5.3 MEXICO
9.5.3.1 Rising investments in biotech research and production to accelerate growth
9.5.4 REST OF LATIN AMERICA
9.6 MIDDLE EAST
9.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST
9.6.2 GCC COUNTRIES
9.6.2.1 Saudi Arabia
9.6.2.1.1 Increasing healthcare expenditure to bolster growth
9.6.2.2 UAE
9.6.2.2.1 Growing focus on biopharmaceutical industry to propel market
9.6.2.3 Rest of GCC Countries
9.6.3 REST OF MIDDLE EAST
9.7 AFRICA
9.7.1 NEED FOR EFFECTIVE DIAGNOSIS OF INFECTIOUS DISEASES TO SUSTAIN GROWTH
9.7.2 MACROECONOMIC OUTLOOK FOR AFRICA

10 COMPETITIVE LANDSCAPE
10.1 OVERVIEW
10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN, 2023
10.3 REVENUE ANALYSIS, 2021-2023
10.4 MARKET SHARE ANALYSIS, 2023
10.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
10.5.1 STARS
10.5.2 EMERGING LEADERS
10.5.3 PERVASIVE PLAYERS
10.5.4 PARTICIPANTS
10.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
10.5.5.1 Company footprint
10.5.5.2 Region footprint
10.5.5.3 Product footprint
10.5.5.4 Application footprint
10.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
10.6.1 PROGRESSIVE COMPANIES
10.6.2 RESPONSIVE COMPANIES
10.6.3 DYNAMIC COMPANIES
10.6.4 STARTING BLOCKS
10.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
10.6.5.1 Detailed list of key startups/SMEs
10.6.5.2 Competitive benchmarking of key startups/SMEs
10.7 COMPANY VALUATION AND FINANCIAL METRICS
10.8 BRAND/PRODUCT COMPARISON
10.9 COMPETITIVE SCENARIO
10.9.1 PRODUCT LAUNCHES
10.9.2 DEALS
10.9.3 EXPANSIONS

11 COMPANY PROFILES
11.1 MAJOR PLAYERS
11.1.1 THERMO FISHER SCIENTIFIC INC.
11.1.1.1 Products offered
11.1.1.2 Recent developments
11.1.1.2.1 Product launches
11.1.1.2.2 Deals
11.1.1.2.3 Expansions
11.1.1.3 MnM view
11.1.1.3.1 Key strengths
11.1.1.3.2 Strategic choices
11.1.1.3.3 Weaknesses and competitive threats
11.1.2 SARTORIUS AG
11.1.2.1 Products offered
11.1.2.2 Recent developments
11.1.2.2.1 Deals
11.1.2.2.2 Expansions
11.1.2.3 MnM view
11.1.2.3.1 Key strengths
11.1.2.3.2 Strategic choices
11.1.2.3.3 Weaknesses and competitive threats
11.1.3 DANAHER CORPORATION
11.1.3.1 Products offered
11.1.3.2 Recent developments
11.1.3.2.1 Product launches
11.1.3.2.2 Deals
11.1.3.2.3 Expansions
11.1.3.3 MnM view
11.1.3.3.1 Key strengths
11.1.3.3.2 Strategic choices
11.1.3.3.3 Weaknesses and competitive threats
11.1.4 MERCK KGAA
11.1.4.1 Products offered
11.1.4.2 Recent developments
11.1.4.2.1 Product launches
11.1.4.2.2 Deals
11.1.4.2.3 Expansions
11.1.5 CORNING INCORPORATED
11.1.5.1 Products offered
11.1.5.2 Recent developments
11.1.5.2.1 Deals
11.1.6 FUJIFILM HOLDINGS CORPORATION
11.1.6.1 Business overview
11.1.6.2 Products offered
11.1.6.3 Recent developments
11.1.6.3.1 Product launches
11.1.6.3.2 Expansions
11.1.7 BECTON, DICKINON & CO
11.1.7.1 Products offered
11.1.7.2 Recent developments
11.1.7.2.1 Product launches
11.1.8 EPPENDORF SE
11.1.8.1 Business overview
11.1.8.2 Products offered
11.1.8.3 Recent developments
11.1.8.3.1 Product launches
11.1.8.3.2 Expansions
11.1.9 LONZA
11.1.9.1 Business overview
11.1.9.2 Products offered
11.1.9.3 Recent developments
11.1.9.3.1 Product launches
11.1.9.3.2 Deals
11.1.10 GETINGE AB
11.1.10.1 Products offered
11.1.10.2 Recent developments
11.1.10.2.1 Product launches
11.1.10.2.2 Deals
11.1.11 ENTEGRIS
11.1.11.1 Business overview
11.1.11.2 Products offered
11.1.12 BIO-RAD LABORATORIES, INC.
11.1.12.1 Business overview
11.1.12.2 Products offered
11.1.13 KURARAY CO., LTD.
11.1.13.1 Business overview
11.1.13.2 Products offered
11.1.13.3 Recent developments
11.1.13.3.1 Product launches
11.1.13.3.2 Expansions
11.1.14 TEIJIN LIMITED
11.1.14.1 Business overview
11.1.14.2 Products offered
11.1.14.3 Recent developments
11.1.14.3.1 Product launches
11.1.15 ASAHI KASEI CORPORATION
11.1.15.1 Business overview
11.1.15.2 Products offered
11.2 OTHER PLAYERS
11.2.1 CELLEVATE AB
11.2.2 PBS BIOTECH, INC.
11.2.3 SOLIDA BIOTECH GMBH
11.2.4 REPROCELL INC.
11.2.5 G&G TECHNOLOGIES, INC.
11.2.6 DENOVOMATRIX GMBH
11.2.7 BIO-LINK
11.2.8 BBI-BIOTECH GMBH
11.2.9 SMART MCS PTY LTD
11.2.10 BIONET

12 APPENDIX
12.1 DISCUSSION GUIDE
12.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
12.3 CUSTOMIZATION OPTIONS
12.4 RELATED REPORTS
12.5 AUTHOR DETAILS